-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, NKGen Biotech announced that the autologous natural killer (NK) cell therapy SNK01, in combination with the PD-1 inhibitor pembrolizumab (Keytruda), is used in the treatment of non-small cell lung cancer (NSCLC) 1 / Phase 2a clinical trial with positive data
The trial enrolled 18 patients with advanced non-small cell lung cancer who had failed previous first-line platinum-based therapy
▲NKGen's innovative NK cell immunotherapy uses high-purity NK cells extracted from the patient's blood, expanded and activated, and then returned to the patient
The trial data showed that patients in the SNK01 combination treatment group achieved a statistically significant better median PFS (6.
Dr.
References:
[1] NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting.